BLAINJECTIONINJECTABLE
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
NYVEPRIA (pegfilgrastim-apgf) by Pfizer is colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Approved for chemotherapy-induced neutropenia, breast cancer, non-hodgkin's lymphoma and 2 more indications. First approved in 2020.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYVEPRIA (pegfilgrastim-apgf) is a long-acting granulocyte colony-stimulating factor (G-CSF) biosimilar approved by Pfizer in June 2020. It is indicated for prevention of infection manifested by febrile neutropenia in patients receiving myelosuppressive chemotherapy. The drug works by binding to cell surface receptors on hematopoietic cells, stimulating proliferation, differentiation, and functional activation of neutrophils.
$0.004BPart D
PeakProduct is at peak lifecycle with $4M Part D spending and modest claim volume; commercial team likely maintaining market presence against established competitors.
Mechanism of Action
colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications (5)
Worked on NYVEPRIA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.